initial phase iii trial results released in august 1997 showed pramlintide did show statistically significant results for type 1 (juvenile-onset) diabetes, helping modestly to improve glucose control without increasing the risk of hypoglycemia (low blood sugar) while also improving weight and cholesterol levels. but adult-onset type 2 diabetes affects far more people than type 1, and pramlintide showed significant benefits only at 6 months but not after 12 months. in march 1998, seven months before the next trial data were due, j&j discontinued its partnership with amylin.